Robeaute has raised $28.0M in total across 1 funding round.
Robeaute's investors include Albion VC, Cherry Ventures, FJ Labs, NFX, Abrahami Avishai.
# Robeauté: Pioneering Neurosurgical Microrobotics
Robeauté is a Paris-based medical technology company developing therapeutic microrobots designed to revolutionize neurosurgery and brain disease treatment[1][2]. The company has created self-propelled microrobots approximately 1.8 millimeters long—about the size of a grain of rice—that can navigate inside the human brain to diagnose, treat, and monitor neurological conditions with unprecedented precision[5].
The company's mission addresses a critical gap in modern medicine: current neurosurgical approaches remain fundamentally limited in their ability to access deep brain structures without causing significant damage. Robeauté's microrobots enable minimally invasive, non-linear navigation to hard-to-reach regions of the brain parenchyma, opening possibilities for tissue biopsies, targeted drug delivery to inoperable brain tumors, and electrode implantation for conditions like Parkinson's disease[2][6]. The company recently secured $28 million in venture capital funding, validating both the technological breakthrough and the massive market opportunity in treating previously incurable brain diseases[3].
Robeauté was founded in 2017 by Bertrand Duplat and Joana Cartocci, bringing together complementary expertise in robotics, operations, and translational medicine[3][6]. Duplat's background is particularly compelling: a 30-year veteran in robotics and semiconductor development, he previously founded four startups, including Virtools—a 3D software company acquired by Dassault Systèmes in 2005[2]. He holds 40 patents and conducted early robotics research at McGill University focused on haptics and complex systems for extreme environments[4].
The genesis of Robeauté carries profound personal weight. Duplat founded the company after his mother died from a brain tumor that was incurable with existing treatments, transforming his technical expertise into a mission-driven venture[2]. Cartocci, now Chief Operating Officer, brought operational excellence from her background managing complex technology projects, including a notable public art installation that transformed the Eiffel Tower during the 2015 COP21 climate talks[3].
The company's early development was extraordinarily challenging. It took five years of interdisciplinary work with multiple laboratories to assemble the foundational building blocks for the microrobot[3]. The breakthrough moment came in December 2021 when the team conducted its first validation tests in animal cadavers, proving the concept could actually work[3]. Since then, Robeauté has progressed to testing in human cadavers and conducting live animal trials, with the company now employing approximately 20 people, primarily scientists recruited from institutions like the Sorbonne's robotics lab[3].
Robeauté has solved engineering problems that no other company in the world has cracked at this scale. The microrobot can drive, steer, and locate itself inside the brain—capabilities that required breakthroughs across robotics, electronics, and microfabrication[2]. The company has been granted more than 50 patents for innovations related to the microsurgical robot's development[3].
Rather than building a single-use tool, Robeauté designed its microrobot as a flexible carrier platform. While the initial commercial focus targets tissue sample collection for biopsies, the same robot can eventually deliver cancer drugs, implant electrodes, or gather diagnostic data—creating multiple revenue streams from a single technological foundation[3][5].
The combination of Duplat's three decades of robotics expertise, serial entrepreneurial success, and deep patent portfolio with Cartocci's operational acumen creates a rare founding duo. This isn't a first-time startup; it's seasoned entrepreneurs applying proven execution capabilities to an entirely new frontier[2][3].
With 50+ patents already granted and a deeply technical problem space, Robeauté has built substantial barriers to competition. The complexity of miniaturizing robotics, power systems, and control mechanisms to operate inside the brain creates a multi-year lead time for potential competitors[3].
Robeauté sits at the intersection of several powerful trends reshaping healthcare and technology. The company is riding the wave of precision medicine—the shift toward targeted, individualized treatments rather than broad-spectrum interventions. Brain diseases represent one of the last great frontiers in medicine, with conditions like Parkinson's, Alzheimer's, and inoperable brain tumors affecting millions globally while remaining largely untreatable with current approaches[2].
The timing is particularly favorable. Advances in miniaturization, materials science, and control systems have only recently made microrobotic surgery feasible. Simultaneously, venture capital has demonstrated appetite for deep-tech medical innovations that solve genuinely hard problems with massive addressable markets. Robeauté's $28 million funding round signals investor confidence in both the technology and the market opportunity[3].
The company also benefits from the broader robotics-in-medicine trend. As surgical robotics (exemplified by da Vinci systems) have proven the value of robotic assistance in the operating room, the logical next step is miniaturization to access previously unreachable anatomy. Robeauté represents the frontier of this evolution.
Beyond commercial impact, Robeauté influences the broader ecosystem by demonstrating that European deep-tech startups can compete globally in highly specialized medical technology. The company's presence at major industry events like MEDICA and BIO International Convention positions it as a thought leader shaping how the medical device industry thinks about minimally invasive neurosurgery[1][6].
Robeauté stands at an inflection point. The company has moved from proof-of-concept to human cadaver testing and is positioned to begin human clinical trials with its fresh capital infusion[2]. The next 18-24 months will be critical: successful human trials would validate the technology and open pathways to regulatory approval, transforming Robeauté from a promising startup into a clinical-stage company with de-risked technology.
The broader trajectory suggests several likely developments. First, the company will likely expand its team significantly, particularly in regulatory affairs and clinical operations, as it navigates the complex path to FDA approval. Second, strategic partnerships with major neurosurgery centers and pharmaceutical companies will become increasingly valuable as Robeauté moves toward commercialization. Third, the company may explore acquisition interest from larger medical device manufacturers seeking to acquire breakthrough technology rather than build it internally.
The market opportunity is staggering. If Robeauté successfully commercializes its microrobot platform, it could fundamentally reshape how neurosurgeons approach brain disease treatment. The addressable market spans neurosurgery, oncology, neurology, and drug delivery—potentially worth billions annually. For investors and the broader medical technology ecosystem, Robeauté represents exactly the kind of deep-tech, mission-driven venture that could generate both substantial financial returns and profound human impact by making previously impossible treatments routine.
Robeaute has raised $28.0M across 1 funding round. Most recently, it raised $28.0M Series A in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $28.0M Series A | Albion VC, Cherry Ventures, FJ Labs, NFX, Abrahami Avishai |
